Abstract
* Dalbavancin (Dalvance) is a new antibiotic approved to treat acute bacterial skin and skin-structure infections caused by gram-positive organisms such as Staphylococcus aureus (both methicillin-susceptible and methicillin-resistant strains) and Streptococcus pyogenes.
* Dalbavancin is administered intravenously. Rapid infusion can lead to red man syndrome. The most common adverse effects are nausea, headache, and diarrhea.